Monitoring Guidelines for At-Home Ketamine

Why Monitoring Matters for At-Home Ketamine

Clinic-based ketamine infusions are administered with continuous or frequent vital sign monitoring because ketamine's cardiovascular effects — transient elevations in blood pressure and heart rate — are predictable and require tracking, especially in patients with any cardiovascular risk factors.

At-home troche therapy trades this monitored environment for convenience and access. The patient is responsible for their own monitoring. Without a framework, monitoring is inconsistent or absent; with a clear framework, at-home patients can safely identify and respond to concerning findings. Our at-home safety checklist provides a session-by-session protocol.

This article describes the monitoring elements that represent standard practice in responsible at-home ketamine programs.

Cardiovascular Monitoring

Why It Matters

Ketamine stimulates sympathetic nervous system activity, producing transient increases in:

• Systolic blood pressure: Typically 10 to 30 mmHg above baseline
• Diastolic blood pressure: 5 to 15 mmHg above baseline
• Heart rate: 10 to 30 beats per minute above resting

For healthy young adults with normal cardiovascular status, these changes are benign and self-resolving. For older patients, those with pre-existing hypertension, or those with underlying cardiovascular disease, these changes may be clinically significant. Review the full list of contraindications before beginning at-home therapy.

Equipment Required

A home automatic blood pressure monitor (sphygmomanometer) is a reasonable requirement for patients who:

• Have any history of hypertension
• Are over 55 years of age
• Have any cardiovascular history
• Are prescribed doses above 150 mg

The American Heart Association recommends upper-arm cuffs over wrist cuffs for more accurate readings. Validated devices that meet AHA/AAMI standards cost $25 to $60 and are readily available.

Pre-Session Blood Pressure Check

Measure and record blood pressure approximately 15 to 30 minutes before placing the troche (before taking anxiety-reducing measures or entering the session space, to get a representative resting value).

General guidance (individual thresholds should be set by your prescriber):

• Under 140/90 mmHg: Proceed with session
• 140/90 to 150/100 mmHg: Proceed with awareness; note in session log; discuss with provider
• Above 150/100 mmHg: Contact provider before proceeding; consider postponing the session

Post-Session Blood Pressure Check

Measure blood pressure 1 to 2 hours after the session ends — when most of the cardiovascular effect should have resolved:

• Elevated values that have returned to near-baseline: Normal and expected
• Persistently elevated values (still >140/90 two hours after session): Contact provider; do not engage in physical activity; rest and re-measure every 30 minutes

Heart Rate Monitoring

Many home blood pressure monitors also measure pulse. Record heart rate alongside blood pressure. Values above 100 bpm before a session warrant consideration; values persistently above 110 bpm after a session warrant contact with the provider.

Patients with known arrhythmias should have explicit heart rate monitoring guidance from their cardiologist or prescriber.

Session-Level Monitoring

Presence of a Support Person

For most patients in the first 5 to 10 sessions, a designated support person (trip sitter) should be present during the session. Their monitoring role includes:

• Confirming the patient is positioned safely before onset
• Checking on the patient periodically during the session (every 20 to 30 minutes)
• Assessing the patient's responsiveness at peak effects (a responsive patient can respond to a simple question; an unresponsive patient requires immediate action)
• Noting start time, troche dissolution, and any observed adverse reactions

The support person does not need medical training, but they should:

• Know the prescriber's after-hours contact information
• Know when to call 911 (persistent unresponsiveness, seizure, chest pain, breathing difficulty)
• Know the patient's medical history and current medications to report if emergency services are called

Self-Monitoring During Sessions

During sessions, patients should:

• Not attempt to drive or leave the session space
• Monitor for unusual physical symptoms: Chest pain, difficulty breathing, severe headache, seizure-like activity — these require immediate support person involvement
• Not take additional doses: Even if effects seem mild

Dissociation Level Assessment

At-home ketamine protocols often use a subjective dissociation scale to help patients and providers communicate about session intensity. A simple 0 to 10 scale:

• 0: No dissociative effects
• 1 to 3: Mild dissociation (present and aware, mild perceptual changes)
• 4 to 6: Moderate dissociation (meaningful altered state, typical therapeutic range)
• 7 to 9: Strong dissociation (significant ego dissolution, may feel overwhelming)
• 10: Profound dissociation ("K-hole" level; loss of coherent experience)

Most therapeutic troche sessions should fall in the 4 to 7 range. Consistent scores of 8 to 10 at a given dose suggest the dose is too high; consistent scores of 0 to 2 suggest the dose may be too low.

Recording a dissociation estimate for each session provides valuable titration data.

Post-Session Monitoring

Cognitive Function Assessment

Before driving, returning to work, or engaging in any activity requiring full cognitive function, patients should perform a brief self-assessment:

• Can I hold a conversation clearly?
• Can I accurately recall where I am and what I've been doing?
• Do I feel fully present and oriented?

Most patients return to cognitive baseline within 2 to 3 hours of a session. Until these questions can be answered confidently, remain in the recovery environment.

Do not drive until at least 4 to 6 hours after the session, regardless of subjective sense of recovery.

Mood Tracking (Days 1 to 7 Post-Session)

The post-session neurobiological effects of ketamine extend for days. Track mood, anxiety, and pain levels daily for at least 5 to 7 days after each session using a simple 0 to 10 scale. This data:

• Reveals how long the therapeutic effect lasts for you specifically
• Guides decisions about session frequency
• Documents response (or non-response) for provider discussions

Adverse Event Monitoring

In the days following a session, note any:

• Persistent cognitive fog lasting more than 24 hours
• Increased frequency or urgency of urination
• Unusual psychological symptoms (sustained paranoia, intrusive trauma material, worsening depression)
• Physical symptoms not clearly related to normal post-session fatigue

Report these to your prescriber at your next appointment or sooner if concerning.

Lab Monitoring

Routine Lab Tests

Most at-home ketamine programs do not require routine blood draws for monitoring. However, some providers order baseline and periodic:

Liver function tests (LFTs): Ketamine is hepatically metabolized; patients with pre-existing liver disease or who develop unexplained symptoms may need LFT monitoring.

Blood pressure log review: Rather than formal lab testing, most cardiovascular monitoring is done through the patient's home BP log reviewed at provider appointments.

Urinalysis or urine culture: If urinary symptoms develop, urological evaluation including urinalysis may be warranted to assess for ketamine cystitis.

For High-Frequency Users

Patients using ketamine more frequently (daily or near-daily sub-dissociative protocols for pain management) face different monitoring needs than patients using once or twice monthly. High-frequency protocols should include:

• More regular LFT monitoring (quarterly)
• Urological symptom assessment at every visit
• More frequent BP tracking

Documentation as Monitoring

Consistent session logging is itself a form of monitoring. When you document:

• Dose and route
• Pre-session BP
• Onset time and intensity
• Post-session BP
• Mood ratings in following days

...you create a longitudinal record that allows both you and your provider to identify trends, outliers, and concerns that might not be apparent from a single appointment.

Monitoring at Provider Appointments

At every follow-up appointment, your provider should:

• Review your session log and BP readings
• Administer standardized symptom measures (PHQ-9, GAD-7 as applicable)
• Ask specifically about urinary symptoms, cognitive changes, and use pattern
• Confirm you're not driving within 4 to 6 hours of sessions
• Assess for any signs of problematic use

Key Takeaways

• Pre-session blood pressure measurement is the most important routine monitoring step; values above 150/100 mmHg warrant provider contact before proceeding.
• A support person is recommended for the first 5 to 10 sessions and any time the dose increases.
• Post-session cognitive function should be fully restored before driving — minimum 4 to 6 hours.
• Track mood for 5 to 7 days after each session; this data guides titration decisions.
• Report persistent urinary symptoms, cognitive changes lasting more than 24 hours, or any unusual physical symptoms to your provider.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service